MTP-131

Phase 1Small molecule

SStealth BioTherapeutics Inc.

MTP-131 is one of 112 small molecule programs targeting Congestive Heart Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congestive Heart FailureActive, not recruiting

Heart FailureActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Congestive Heart FailurePhase 1

Active, not recruiting

Heart FailurePhase 1

Active, not recruiting

Age-Related Macular DegenerationPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Medrol

Pfizer

Preclinical

1 3

Brethine

Sanofi

Preclinical

1 4

LCZ696

Novartis

Preclinical

15 5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Xifaxan

SSalix

Preclinical

2 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 10

Adriamycin

GGynecologic Oncology Group

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure1 trial

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure

Withdrawn·SStealth BioTherapeutics Inc.·Phase 1·NCT02388529

Congestive Heart Failure1 trial

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

Completed·SStealth BioTherapeutics Inc.·Phase 1·NCT02388464·36 enrolled

Impaired Renal Function1 trial

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

Completed·SStealth BioTherapeutics Inc.·Phase 1·NCT02436447·23 enrolled

Age-Related Macular Degeneration1 trial

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

Completed·SStealth BioTherapeutics Inc.·Phase 1/2·NCT02314299·20 enrolled

Intravenous1 trial

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Completed·SStealth BioTherapeutics Inc.·Phase 1·NCT01115920·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MTP-131. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MTP-131 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MTP-131. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stealth BioTherapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SStealth BioTherapeutics Inc.

MTP-131

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure1 trial

Congestive Heart Failure1 trial

Impaired Renal Function1 trial

Age-Related Macular Degeneration1 trial

Intravenous1 trial

References

Drug Info

Quick Facts

Related News